276 related articles for article (PubMed ID: 31804676)
1. Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer.
Cespedes Feliciano EM; Chen WY; Lee V; Albers KB; Prado CM; Alexeeff S; Xiao J; Shachar SS; Caan BJ
JAMA Oncol; 2020 Feb; 6(2):264-270. PubMed ID: 31804676
[TBL] [Abstract][Full Text] [Related]
2. Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer.
Caan BJ; Cespedes Feliciano EM; Prado CM; Alexeeff S; Kroenke CH; Bradshaw P; Quesenberry CP; Weltzien EK; Castillo AL; Olobatuyi TA; Chen WY
JAMA Oncol; 2018 Jun; 4(6):798-804. PubMed ID: 29621380
[TBL] [Abstract][Full Text] [Related]
3. Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane-Based Chemotherapy for Early-Stage Breast Cancer.
Shachar SS; Deal AM; Weinberg M; Williams GR; Nyrop KA; Popuri K; Choi SK; Muss HB
Clin Cancer Res; 2017 Jul; 23(14):3537-3543. PubMed ID: 28143874
[No Abstract] [Full Text] [Related]
4. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.
Rugo HS; Klein P; Melin SA; Hurvitz SA; Melisko ME; Moore A; Park G; Mitchel J; Bågeman E; D'Agostino RB; Ver Hoeve ES; Esserman L; Cigler T
JAMA; 2017 Feb; 317(6):606-614. PubMed ID: 28196257
[TBL] [Abstract][Full Text] [Related]
5. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity.
Chavez-Macgregor M; Litton J; Chen H; Giordano SH; Hudis CA; Wolff AC; Valero V; Hortobagyi GN; Bondy ML; Gonzalez-Angulo AM
Cancer; 2010 Sep; 116(17):4168-77. PubMed ID: 20564153
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
[TBL] [Abstract][Full Text] [Related]
7. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy.
Farr A; Stolz M; Baumann L; Bago-Horvath Z; Oppolzer E; Pfeiler G; Seifert M; Singer CF
Breast; 2017 Jun; 33():153-158. PubMed ID: 28395233
[TBL] [Abstract][Full Text] [Related]
8. Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59 at diagnosis: A nationwide study.
Chung IY; Lee JW; Moon HG; Shin KH; Han W; Son BH; Ahn SH; Noh DY
Breast; 2020 Oct; 53():125-129. PubMed ID: 32771950
[TBL] [Abstract][Full Text] [Related]
9. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study.
Cespedes Feliciano EM; Lee VS; Prado CM; Meyerhardt JA; Alexeeff S; Kroenke CH; Xiao J; Castillo AL; Caan BJ
Cancer; 2017 Dec; 123(24):4868-4877. PubMed ID: 28881381
[TBL] [Abstract][Full Text] [Related]
10. Re: Lymphopenia associated with adjuvant anthracycline/taxane regimens.
Cadoo K; Lowery M; McCaffrey J
Clin Breast Cancer; 2009 Nov; 9(4):262. PubMed ID: 19933084
[No Abstract] [Full Text] [Related]
11. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial.
Nangia J; Wang T; Osborne C; Niravath P; Otte K; Papish S; Holmes F; Abraham J; Lacouture M; Courtright J; Paxman R; Rude M; Hilsenbeck S; Osborne CK; Rimawi M
JAMA; 2017 Feb; 317(6):596-605. PubMed ID: 28196254
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
[TBL] [Abstract][Full Text] [Related]
13. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.
Pérez-Fidalgo JA; Bermejo B; Chirivella I; Martínez MT; González I; Cejalvo JM; Catoira I; Martínez P; Contel E; Lluch A
Clin Transl Oncol; 2014 Sep; 16(9):814-22. PubMed ID: 24532305
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
Rosenstock AS; Niu J; Giordano SH; Zhao H; Wolff AC; Chavez-MacGregor M
Cancer; 2018 Mar; 124(5):899-906. PubMed ID: 29236294
[TBL] [Abstract][Full Text] [Related]
16. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.
Chirivella I; Bermejo B; Insa A; Pérez-Fidalgo A; Magro A; Rosello S; García-Garre E; Martín P; Bosch A; Lluch A
Breast Cancer Res Treat; 2009 Apr; 114(3):479-84. PubMed ID: 18463977
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial.
Abdel-Rahman O
Clin Transl Oncol; 2019 Feb; 21(2):239-245. PubMed ID: 29956074
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy.
Fumoleau P; Cortés-Funes H; Taleb AB; Chan S; Campone M; Pouget JC; Tubiana-Hulin M; Slabber CF; Caroff-Paraïso I; Alberts AS; Ben Ayed F
Am J Clin Oncol; 2009 Aug; 32(4):375-80. PubMed ID: 19487917
[TBL] [Abstract][Full Text] [Related]
19. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
Shayne M; Crawford J; Dale DC; Culakova E; Lyman GH;
Breast Cancer Res Treat; 2006 Dec; 100(3):255-62. PubMed ID: 16705366
[TBL] [Abstract][Full Text] [Related]
20. [Management of anthracycline and taxane therapy-induced symptoms for the patients with breast cancer].
Fukada I; Ito Y
Nihon Rinsho; 2015 Feb; 73 Suppl 2():548-52. PubMed ID: 25831820
[No Abstract] [Full Text] [Related]
[Next] [New Search]
